Naresh Mullaguri1, Madihah Hepburn1, James Matthew Gebel1,2, Ahmed Itrat1,2, Pravin George1, Christopher R Newey1,3. 1. Cerebrovascular Center, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. 2. Section of Neurology, Cleveland Clinical Akron General Hospital, Akron, OH, USA. 3. Epilepsy Center, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Abstract
INTRODUCTION: SARS-Coronavirus-2 infection leading to COVID-19 disease presents most often with respiratory failure. The systemic inflammatory response of SARS-CoV-2 along with the hypercoagulable state that the infection elicits can lead to acute thrombotic complications including ischemic stroke. We present 3 cases of patients with COVID-19 disease who presented with varying degrees of vascular thrombosis. CASES: Cases 1 and 2 presented as cerebral ischemic strokes without respiratory failure. Given their exposure risks, they were both tested for COVID-19 disease. Case 2 ultimately developed respiratory failure and pulmonary embolism. Cases 2 and 3 were found to have simultaneous arterial and venous thromboembolism (ischemic stroke and pulmonary embolism) as well as positive antiphospholipid antibodies. CONCLUSION: Our case series highlight the presence of hypercoagulability as an important mechanism in patients with COVID-19 disease with and without respiratory failure. Despite arterial and venous thromboembolic events, antiphospholipid and hypercoagulable panels in the acute phase can be difficult to interpret in the context of acute phase response and utilization of thrombolytics. SARS-CoV-2 testing in patients presenting with stroke symptoms may be useful in communities with a high case burden or patients with a history of exposure.
INTRODUCTION: SARS-Coronavirus-2 infection leading to COVID-19 disease presents most often with respiratory failure. The systemic inflammatory response of SARS-CoV-2 along with the hypercoagulable state that the infection elicits can lead to acute thrombotic complications including ischemic stroke. We present 3 cases of patients with COVID-19 disease who presented with varying degrees of vascular thrombosis. CASES: Cases 1 and 2 presented as cerebral ischemic strokes without respiratory failure. Given their exposure risks, they were both tested for COVID-19 disease. Case 2 ultimately developed respiratory failure and pulmonary embolism. Cases 2 and 3 were found to have simultaneous arterial and venous thromboembolism (ischemic stroke and pulmonary embolism) as well as positive antiphospholipid antibodies. CONCLUSION: Our case series highlight the presence of hypercoagulability as an important mechanism in patients with COVID-19 disease with and without respiratory failure. Despite arterial and venous thromboembolic events, antiphospholipid and hypercoagulable panels in the acute phase can be difficult to interpret in the context of acute phase response and utilization of thrombolytics. SARS-CoV-2 testing in patients presenting with stroke symptoms may be useful in communities with a high case burden or patients with a history of exposure.
Authors: Arvind Chandratheva; David J Werring; Rahma Beyrouti; Matthew E Adams; Laura Benjamin; Hannah Cohen; Simon F Farmer; Yee Yen Goh; Fiona Humphries; Hans Rolf Jäger; Nicholas A Losseff; Richard J Perry; Sachit Shah; Robert J Simister; David Turner Journal: J Neurol Neurosurg Psychiatry Date: 2020-04-30 Impact factor: 10.154
Authors: Thomas J Oxley; J Mocco; Shahram Majidi; Christopher P Kellner; Hazem Shoirah; I Paul Singh; Reade A De Leacy; Tomoyoshi Shigematsu; Travis R Ladner; Kurt A Yaeger; Maryna Skliut; Jesse Weinberger; Neha S Dangayach; Joshua B Bederson; Stanley Tuhrim; Johanna T Fifi Journal: N Engl J Med Date: 2020-04-28 Impact factor: 91.245
Authors: F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman Journal: Thromb Res Date: 2020-04-10 Impact factor: 3.944